BioSpace News Archive

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced financial results for the second quarter of 2022.

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results.

Motus GI Holdings, Inc. announced that it received formal notice from the Nasdaq Stock Market stating that the Company has regained compliance with the minimum bid price requirement ) for continued listing on Nasdaq and that Motus GI’s common stock will continue to be listed and traded on Nasdaq.

LumiraDx Limited (Nasdaq: LMDX ), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022.

aTyr Pharma, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for its lead therapeutic candidate, efzofitimod (ATYR1923).

F-star Therapeutics, Inc. today announced second quarter 2022 financial results and corporate highlights.

Fortress Biotech, Inc. today announced that Triplex, a cytomegalovirus (“CMV”) vaccine being developed by its subsidiary Helocyte, Inc. (“Helocyte”), received a grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (“NIAID/NIH”) that could provide over $20 million in non-dilutive funding.

Surrozen, Inc. today reported financial results for the second quarter of 2022 and provided a corporate update.

89bio, Inc. today reported its financial results for the quarter ended June 30, 2022.

Synthetic Biologics, Inc today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.